Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
4,974 total articles
Adaptive Biotechnologies Corp. executive Julie Rubinstein sold 57,180 shares of common stock between March 27 and March 31, 2026, generating about $751,302 in proceeds from prices between $12.07 and $13.87. The transactions accompanied the exercise of stock options that produced 44,166 shares at $7.27 each. The trades were carried out under a Rule …
Palladyne AI Corp (NASDAQ: PDYN) Chief Financial Officer Trevor Thatcher disposed of 3,030 shares on March 30, 2026 to satisfy income tax obligations tied to recently vested restricted stock units. The sale, executed across multiple trades at prices between $5.295 and $5.6301 for an average of $5.5463, totaled $16,805. After the transactions, Thatc…
Palladyne AI Corp. (OTC: PDYN) Chief Legal Officer Stephen Sonne reported the sale of 3,471 common shares on March 30, 2026, in a Form 4 filing with the SEC. The shares were sold to satisfy income tax liabilities tied to vested restricted stock units and fetched a weighted average price of $5.5463, for total proceeds of $19,251. The stock has since…
Palladyne AI Corp. Chief Technology Officer Denis Garagic sold 15,149 shares of common stock on March 30, 2026, raising $84,020 at a weighted average price of $5.5463 to meet income tax liabilities tied to vested restricted stock units. The company has reported large year-over-year revenue gains for Q4 2025 and secured defense contracts, while its …
BFI Co., LLC, a roughly 10% holder of Phibro Animal Health Corp (NASDAQ: PAHC), sold 14,080 Class A shares on March 30-31, 2026 for about $756,833 under a Rule 10b5-1 plan adopted in December 2025. After the transactions, BFI Co. directly holds 38,120 shares. Jack Bendheim, Phibro’s President and CEO, exercises voting and dispositive power over BFI…
Kimberly D. Campos, chief investment officer and chief accounting officer at Universal Insurance Holdings (NASDAQ: UVE), sold 946 shares on March 31, 2026, for $34.12 per share, totaling $32,277. The Form 4 filing also reports an option exercise for 1,251 shares at a $0 strike and the withholding of 305 shares on March 27, 2026, to satisfy tax obli…
Daxor CORP Chief Financial Officer Robert J. Michel purchased 1,000 shares of company stock for $9.90 per share on March 31, 2026, bringing his direct holding to 21,050 shares. The transaction coincides with a stock price trading below the purchase level, recent operating revenue growth, an increase in net assets and a completed registered direct o…
C3.ai director Snabe Jim H. sold 10,000 Class A shares for $8.08 apiece and, on the same day, bought 10,000 Class A shares at $7.73, leaving him with a stated direct holding of 385,000 shares and an indirect stake of 28,000 through BJHS Invest ApS. The transactions come amid a difficult quarter for the enterprise AI company - fiscal Q3 results mate…
Universal Insurance Holdings director Richard D. Peterson sold 2,000 shares on March 30, 2026, generating roughly $68,207 in proceeds at prices between $34.06 and $34.14 per share. The transaction occurred while UVE shares trade near a 52-week high and after the company reported a sizable earnings-per-share beat for the fourth quarter of 2025, even…
Christopher E. Kevane, Executive Vice President and Chief Legal Officer of Universal Technical Institute (NYSE:UTI), executed a sale of 23,654 shares on March 27, 2026, according to a Form 4 filing. The transaction totaled $888,115 at a weighted average price of $37.5461. The sale accompanies a recent week-long share decline and follows the company…
Ligand Pharmaceuticals director John L. LaMattina sold 2,161 shares on March 6, 2026, at $200.76 per share for $433,842 and on the same day exercised options to acquire 2,161 shares at $114.15 for $246,678. After the transactions LaMattina holds 30,724 direct shares. The stock has gained about 90% over the past year and is trading near $199.65. Sep…
Guidewire Software CEO Michael George Rosenbaum sold 1,200 shares on March 30, 2026, through an automatic 10b5-1 schedule. The transaction totaled $174,888 and left Rosenbaum with 218,806 shares. The stock trades below recent levels and InvestingPro labels GWRE among the Most Overvalued. Separately, Guidewire posted fiscal second-quarter results th…
Laura Lee Stewart, president and chief executive of Sound Financial Bancorp, reported the sale of 900 common shares on March 31, 2026, in a Form 4 filing with the SEC. The shares were sold at $44.13 apiece for a total of $39,717. Following the transaction, Stewart continues to hold substantial direct and indirect positions in the company, which has…
Rebecca E. Zorn, Globe Life Inc.'s EVP and Chief Talent Officer, sold $1,202,189 of company stock on March 31, 2026 in three transactions after exercising options to acquire 8,800 shares at $98.32. The filings detail sale prices between $135.6593 and $137.4038. The disclosures come amid a recent quarterly earnings miss, a dividend increase, board e…
Stanford Gertz, a director at Strawberry Fields REIT, Inc. (NASDAQ: STRW), purchased 392 shares on March 13, 2026, at $12.89 per share for a total of $5,052, increasing his direct holding to 819 shares. The transaction was disclosed in a Form 4 filing with the SEC. Separately, the company declared a $0.16 per share cash dividend for Q1 2026 and dis…
Roland Thomas Kelly, Chief Legal Officer and General Counsel of Velocity Financial, Inc. (NYSE: VEL), sold 14,840 shares of the company's common stock across two trades on March 30 and March 31, 2026, receiving $267,771 in total proceeds. The disposals occurred amid a backdrop of robust fourth-quarter fiscal 2025 results and divergent valuation ass…
SoftVest, LP purchased 68,467 units of Cross Timbers Royalty Trust (NYSE: CRT) on March 27, 2026, paying a weighted average price of $10.24 per unit for a total of $701,102. Following the acquisition the firm directly holds 697,851 units. The move coincides with a recent 16% one-week gain in CRT shares and a near 40% year-to-date rise, though third…
Karen A. Foster, Chief Quality and Operations at BioLife Solutions Inc (NASDAQ: BLFS), sold 2,577 shares on March 23, 2026, under a Rule 10b5-1 trading plan. The transaction, executed at a weighted average price of $19.17, totaled $49,401 and leaves Foster with 108,758 shares held directly. The sale occurs while BLFS is trading close to its 52-week…
Asana Inc.'s Chief Financial Officer, Megji Aziz, sold 30,650 Class A shares on March 27, 2026, receiving $6.1033 per share for a total of $187,066. The transaction was carried out under a pre-established Rule 10b5-1 plan and follows recent company results and multiple analyst price-target reductions. Aziz continues to hold 224,549 shares after the…
Rapport Therapeutics Chief Operating Officer Cheryl Gault sold 10,000 shares of the company's common stock on March 30, 2026, in two transactions totaling $281,857 under a Rule 10b5-1 trading plan. The company recently reported fiscal 2025 results and Phase IIa data for RAP-219 in focal seizures, and plans to begin two Phase 3 studies in the second…
Director Lu Hongbo bought 75,000 shares of Zenas BioPharma, Inc. (NASDAQ: ZBIO) on March 31, 2026, at $20.00 per share, a $1.5 million purchase executed through an underwritten public offering. The acquisition increases Lu's indirect holdings to 422,968 shares. The company concurrently announced a $200 million convertible note offering and a 5 mill…
Macy's Executive Vice President and Chief Human Resources Officer Danielle L. Kirgan sold 5,161 shares of Macy's common stock on March 30, 2026 for $91,515 after exercising 11,256 restricted stock units on March 28. The stock trades at $18.10, and third-party analysis places the company near a fair value of $17.74 with a low P/E of 7.8. Macy's repo…
Rezolute Chief Financial Officer Daron Evans purchased 10,000 common shares on March 30, 2026, acquiring stock worth $28,500 at $2.85 per share, increasing his direct holdings to 414,462 shares. The buy comes amid a roughly 70% six-month decline in the stock and ongoing regulatory engagement with the FDA over the company’s ersodetug program for con…
Martine Rothblatt, chairperson and CEO of United Therapeutics (UTHR), sold $5.6 million of company stock on March 30, 2026 under a pre-arranged 10b5-1 trading plan and exercised options to acquire additional shares the same day. The transactions come amid a wave of analyst updates following positive Phase 3 TETON-1 results for the company’s Tyvaso …
Epsilon Energy Ltd. CEO Jason Stabell bought 20,000 common shares between March 27 and March 31, 2026, spending $124,180 across three transactions reported on a Form 4 filing. The purchases come after a quarterly earnings beat and amid a substantial year-to-date share-price gain; the stock traded at $6.16 at the close, down 0.65%.
